More from Bruce Booth with a realistic (and pessimistic) perspective on diagnostic investments and related challenges.

Key question:

“…how does one generate a return from early stage diagnostic investing – the translation of academia-derived insights into new clinically-validated diagnostic tests. Who is going to fund the next generation of new innovative Dx plays?”

Unhealthy Prognosis for Venture-Backed Diagnostics – Forbes.